Long-term malaria prophylaxis for travelers

Journal of Travel Medicine

Volumn 11, Issue 6, 2004, Pages 374-378

  Knobloch, Jürgen ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b Institute for Tropical Medicine   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATOVAQUONE PLUS PROGUANIL; CHLOROQUINE; DOXYCYCLINE; FANSIDAR; FANSIMEF; MALOPRIM; MEFLOQUINE; PRIMAQUINE; PROGUANIL; TAFENOQUINE;

CHEMOPROPHYLAXIS; DRUG INDICATION; HUMAN; LONG TERM CARE; MALARIA; MALARIA CONTROL; MALARIA FALCIPARUM; MEDICAL INFORMATION; MENTAL DISEASE; NEUROLOGIC DISEASE; NONHUMAN; PATIENT COMPLIANCE; PLASMODIUM FALCIPARUM; PLASMODIUM OVALE; PLASMODIUM VIVAX; PSYCHOPATHY; RETINOPATHY; REVIEW; RISK ASSESSMENT; TRAVEL;

EID: 10344240348     PISSN: 11951982     EISSN: None     Source Type: Journal    
DOI: 10.2310/7060.2004.19207     Document Type: Review

References (40)

1. Hughes C, Tucker R, Bannister B, et al. Malaria prophylaxis for long-term travellers. Commun Dis Public Health 2003; 6:200-208.
2. German Society of Tropical Medicine. Empfehlungen zur Malariaprophylaxe. Personen mit längeren oder häufig wiederholten Tropenaufenthalten. 2003. Available at: http://www.dtg.mwn.de/malaria/langzeit.htm (accessed April 28, 2004).
3. Centers for Disease Control and Prevention. Travelers' health. 2003. Available at: http://www.cdc.gov/travel/malariadrugs2.htm (accessed April 28, 2004).
4. World Health Organization. International travel and health. Geneva: World Health Organization, 2003.
5. Zucker JR, Carnevale PJ. Malaria. Epidemiology and prevention of exposure. In: Du Pont HL, Steffen R, eds. Textbook of travel medicine and health. Hamilton: BC Decker, 1997:101-108.
6. Klement E, Chauveheid MP, Thellier M, et al. Subacute clinical forms of Plasmodium falciparum malaria in travelers receiving chloroquine-proguanil prophylaxis. Clin Infect Dis 2001; 33:1614-1615.
7. Hogh B, Clarke PD, Camus D, et al for the Malarone International Study Team. Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: a randomised, double-blind study. Lancet 2000; 356:1888-1894.
8. Knobloch J, ed. Malaria. Grundlagen und klinische Praxis. Bremen: UNI-MED Verlag, 2003.
9. Fradin MS, Day JF. Comparative efficacy of insect repellents against mosquito bites. N Engl J Med 2002; 347:13-18.
10. Fegan D, Glennon J. Malaria prophylaxis in long-term expatriate mineworkers in Ghana. Occup Med 1993; 43:135-138.
11. Chatterjee S. Compliance of malaria chemoprophylaxis among travelers to India. J Travel Med 1999; 6:7-11.
12. Philipps J, Radloff PD, Lehman LG, et al. Clinical diagnosis of malaria: can the patients help us improve? Trans R Soc Trop Med Hyg 1996; 90:42.
13. United States Sanitary Commission. Report of a committee appointed by resolution of the sanitary commission, to prepare a paper on the use of quinine as a prophylactic against malarious diseases. New York: WMC Bryant & Co., 1861.
14. Stemberger H, Leimer R, Wiedermann G. Tolerability of long-term prophylaxis with Fansidar: a randomized double-blind study in Nigeria. Acta Trop 1984; 41:391-399.
15. Hellgren U, Angel VH, Bergqvist Y, et al. Plasma concentrations of sulfadoxine-pyrimethamine and of mefloquine during regular long-term malaria prophylaxis. Trans R Soc Trop Med Hyg 1990; 84:46-49.
16. Rombo L, Angel VH, Friman G, et al. Comparative tolerability and kinetics during long-term intake of Lariam and Fansidar for malaria prophylaxis in nonimmune volunteers. Trop Med Parasitol 1993; 44:254-256.
17. Kollaritsch H, Stemberger H, Mailer H, et al. Tolerability of long-term malaria prophylaxis with the combination mefloquine + sulfadoxine + pyrimethamine (Fansimef): results of a double-blind field trial versus chloroquine in Nigeria. Trans R Soc Trop Med Hyg 1988; 82:524-529.
18. Cook IF, Kish MY. Haematological safety of long-term malarial prophylaxis with dapsone-pyrirnethamine. Med J Aust 1985; 143:139-141.
19. Lange WR, Frankenfield DL, Moriartry-Sheehan M, et al. No evidence for chloroquine-associated retinopathy among missionaries on long-term malaria chemoprophylaxis. Am J Trop Med Hyg 1994; 51:389-392.
20. Bertagnolio S, Tacconelli E, Camilli G, Tumbarello M. Case report: retinopathy after malaria prophylaxis with chloroquine. Am J Trop Med Hyg 2001; 65:637-638.
21. Lobel HO, Bernard KW, Williams SL, et al. Effectiveness and tolerance of long-term malaria prophylaxis with mefloquine. Need for a better dosing regimen. JAMA 1991; 265:361-364.
22. Peragallo MS, Sabatinelli G, Sarnicola G. Compliance and tolerability of mefloquine and chloroquine plus proguanil for long-term malaria chemoprophylaxis in groups at particular risk (the military). Trans R Soc Trop Med Hyg 1999; 93:73-77.
23. Schlagenhauf P. Mefloquine for malaria chemoprophylaxis 1992-1998: a review. J Travel Med 1999; 6:122-133.
24. Lobel HO, Miani M, Eng T, Bernard KW, et al. Long-term malaria prophylaxis with weekly mefloquine. Lancet 1993; 341:848-851.
25. Hopperus Buma APCC, van Thiel PPAM, Lobel HO, et al. Long-term malaria chemoprophylaxis with mefloquine in Dutch marines in Cambodia. J Infect Dis 1996; 173:1506-1509.
26. Jaspers CAJJ, Hopperus Buma APCC, van Thiel PPAM, et al. Tolerance of mefloquine chemoprophylaxis in Dutch military personnel. Am J Trop Med Hyg 1996; 55:230-234.
27. Pennie RA, Koren G, Crevoisier C. Steady state pharmacokonetics of mefloquine in long-term travellers. Trans R Soc Trop Med Hyg 1993; 87:459-462.
28. Schwartz E, Potasman I, Rotenberg M, et al. Serious adverse events of mefloquine in relation to blood levels and gender. Am J Trop Med Hyg 2001; 65:189-192.
29. Shanks GD, Roessler F, Edstein MD, et al. Doxycycline for malaria prophylaxis in Australian soldiers deployed to United Nations missions in Somalia and Cambodia. Mil Med 1995; 160:443-445.
30. Raoult D, Houpikian P, Tissot Dupont H, et al. Treatment of Q fever endocarditis: comparison of 2 regimens containing doxycycline and ofloxacin or hydroxychloroquine. Arch Intern Med 1999; 159:167-173.
31. Baxter BT, Pearce WH, Waltke EA, et al. Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: report of a prospective (Phase II) multicenter study. J Vasc Surg 2002; 36:1-12.
32. Watanasook C, Singharaj P, Suriyamongkol V, et al. Malaria prophylaxis with doxycycline in soldiers deployed to Thai-Kampuchean border. Southeast Asian J Trop Med Public Health 1989; 20:61-64.
33. Pages F, Boutin JP, Meynard JB, et al. Tolerability of doxycycline monohydrate salt vs. chloroquine proguanil in malaria chemoprophylaxis. Trop Med Int Health 2002; 7:919-924.
34. Ling J, Baird JK, Fryauff DJ, et al. Randomized, placebo-controlled trial of atovaquone/proguanil for the prevention of Plasmodium falciparum or Plasmodium vivax malaria among migrants to Papua, Indonesia. Clin Infect Dis 2002; 35:825-833.
35. Petersen E. The safety of atovaquone/proguanil in long-term malaria prophylaxis of nonimmune adults. J Travel Med 2003; 10(Suppl 1):S13-S15.
36. Overbosch D. Post-marketing surveillance: adverse events during long-term use of atovaquone/proguanil for travelers to malaria-endemic countries. J Travel Med 2003; 10(Suppl 1):S16-S20.
37. Overbosch D, Schilthuis H, Bienzle U, et al. Atovaquoneproguanil versus mefloquine for malaria prophylaxis in non-immune travelers: results from a randomized, double-blind study. Clin Infect Dis 2001; 33:1015-1021.
38. Baird JK, Lacy MD, Basri H, et al. Randomized, parallel placebo-controlled trial of primaquine for malaria prophylaxis in Papua, Indonesia. Clin Infect Dis 2001; 33:1990-1997.
39. Fryauff DJ, Baird JK, Basri H, et al. Randomised placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria. Lancet 1995; 346:1190-1193.
40. Shanks GD, Oloo AJ, Aleman GM, et al. A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria. Clin Infect Dis 2001; 33:1968-1974.